GSK shingles vaccine shows benefits across all age groups
Goldman Sachs analysts said in a report on Tuesday that efficacy across age groups gives HZ/su a meaningful edge over Zostavax, and GSK's product had the potential to achieve peak sales of around 1 billion pounds ($1.5 billion) a year.
Agenus Inc. (including its subsidiaries, also referred to as “Agenus,” the .... presenting at least three product candidates at .... Society of Clinical Oncology, or ASCO ( ASCO 2015 Conquer Cancer Foundation )
Cancer Immunotherapy Remains Hot as Aduro Biotech Doubles In Value On IPO Debut
| 04/15/15 - 11:35 AM ED